Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2).
Publication
, Journal Article
Crawford, J; Duch, DS; Gralla, RJ; Hillner, BE; Hollen, PJ; Vokes, EE
Published in: Semin Oncol
April 1996
Duke Scholars
Published In
Semin Oncol
ISSN
0093-7754
Publication Date
April 1996
Volume
23
Issue
2 Suppl 5
Start / End Page
53 / 55
Location
United States
Related Subject Headings
- Radiation-Sensitizing Agents
- Quality of Life
- Oncology & Carcinogenesis
- Lung Neoplasms
- Humans
- Drug Costs
- Costs and Cost Analysis
- Combined Modality Therapy
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Agents
Citation
APA
Chicago
ICMJE
MLA
NLM
Crawford, J., Duch, D. S., Gralla, R. J., Hillner, B. E., Hollen, P. J., & Vokes, E. E. (1996). Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2). Semin Oncol, 23(2 Suppl 5), 53–55.
Crawford, J., D. S. Duch, R. J. Gralla, B. E. Hillner, P. J. Hollen, and E. E. Vokes. “Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2).” Semin Oncol 23, no. 2 Suppl 5 (April 1996): 53–55.
Crawford J, Duch DS, Gralla RJ, Hillner BE, Hollen PJ, Vokes EE. Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2). Semin Oncol. 1996 Apr;23(2 Suppl 5):53–5.
Crawford, J., et al. “Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2).” Semin Oncol, vol. 23, no. 2 Suppl 5, Apr. 1996, pp. 53–55.
Crawford J, Duch DS, Gralla RJ, Hillner BE, Hollen PJ, Vokes EE. Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2). Semin Oncol. 1996 Apr;23(2 Suppl 5):53–55.
Published In
Semin Oncol
ISSN
0093-7754
Publication Date
April 1996
Volume
23
Issue
2 Suppl 5
Start / End Page
53 / 55
Location
United States
Related Subject Headings
- Radiation-Sensitizing Agents
- Quality of Life
- Oncology & Carcinogenesis
- Lung Neoplasms
- Humans
- Drug Costs
- Costs and Cost Analysis
- Combined Modality Therapy
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Agents